Danish diabetes giant Novo Nordisk (NOV: N) today reported financial results for the first quarter of 2024, noting that sales ...

San Diego, USA-based clinical-stage cell and gene therapy company Poseida Therapeutics (Nasdaq: PSTX) saw its shares close up more than 20% at $2.92 yesterday, when it revealed a second ...

Subsidies for Danish drugmaker giant Novo Nordisk’s diabetes drug Ozempic (semaglutide) will be restricted in its home country due to rising public spending on the blockbuster diabetes medicine, which ...

Shares in US mRNA specialist Moderna (Nasdaq: MRNA) were 7% higher during Thursday morning’s trading. The Boston-based company earlier announced its financial results for the first quarter of 2024 and ...

Californian biotech Enlaza Therapeutics has raised $100 million in a series A financing led by J.P. Morgan Asset Management’s Private Capital division.

This increased understanding of disease biology is allowing argenx and other biotech companies to develop medicines that block IgG recycling by FcRn and may result in new treatment options for people ...

UK clinical-stage biotech Barinthus Biotherapeutics, formerly Vaccitech, today announced the appointment of Dr Leon Hooftman as chief medical officer (CMO).

UK-based developer of novel immunoglobulin E (IgE) antibodies to treat cancer, Epsilogen, has appointed Ashley Nagle as chief business officer (CBO) with immediate effect as part of a broader ...

Under the multi-program agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify and optimize novel macrocyclic peptides against targets ...

Along with all the other medicines supply problems that the country has recently encountered, Russia is now facing a shortage of anti-HIV drugs, despite a significant increase of their procurements by ...

US pharma giant Merck & Co has announced results from STRIDE-10, a Phase III trial of V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine (PCV), at the ...

Shares of USA-based Regeneron (Nasdaq: REGN) dipped 1.8% after reporting first-quarter 2024 financial results that fell short of Wall Street expectations. The biotechnology company announced an ...